August 2024
Accelerating Sales of Eisai and Biogen’s Alzheimer’s Drug Leqembi in Japan
Leqembi, Alzheimer’s drug, Eisai, Biogen, Japan, sales acceleration
23andMe Board Rejects CEO Anne Wojcicki’s Take-Private Plan, Requests Changes
23andMe, Anne Wojcicki, take-private plan, board rejection, financing, stock price, shareholders
Novartis Intensifies Entresto Defense with FDA Complaint Amid Patent Lawsuits
Novartis, Entresto, FDA complaint, patent lawsuits, pharmaceuticals
Agios’ Pyrukynd Misses Primary Endpoint in First Pediatric Study for Rare Blood Disorder
Agios Pharmaceuticals, Pyrukynd, mitapivat, PK deficiency, pediatric study, blood disorder, Phase 3 ACTIVATE-KidsT study
Vir Biotechnology Acquires T-Cell Engagers from Sanofi, Reduces Staff by 25% in Strategic Pipeline Shift
Vir Biotechnology, Sanofi, T-cell engagers, pipeline switch-up, staff reduction, biotech industry, pharmaceuticals
Impact of New CDC Guidelines on RSV Vaccine Makers
RSV vaccine, CDC guidelines, vaccine makers, Moderna, Pfizer, GSK, Guillain-Barré syndrome, vaccination recommendations
Vir Biotechnology Lays Off 25% of Staff, Shifts Focus to Cancer Research in Sanofi Partnership
Vir Biotechnology, layoffs, Sanofi partnership, cancer research, monoclonal antibodies
Biopharma Layoff Tracker 2024: uniQure, Vir, Arbutus, and More Cut Staff
biopharma layoffs, uniQure, Vir, Arbutus, biotech industry, job cuts, restructuring initiatives
Vertex Pharmaceuticals Abandons Two Phase I AATD Drug Candidates Due to Disappointing Data
Vertex Pharmaceuticals, AATD, alpha-1 antitrypsin deficiency, drug candidates, Phase I trials, disappointing data
GSK Secures Broad Label Expansion for Jemperli in First-Line Endometrial Cancer
GSK, Jemperli, dostarlimab, endometrial cancer, FDA approval, chemotherapy, immuno-oncology, Keytruda, Merck